Accéder directement au contenu Accéder directement à la navigation
Brevet

Drug delivery system for platinum-based drugs

Abstract : The present invention concerns the nanomedicine field for anticancer therapy. The treatment of cancer using plat¬ inum-based compounds comprises certain drawbacks such as biocompatibility, loading efficacy, leakage of drugs during storage and in the bloodstream, more particularly due to the nature of the nanocarriers for platinum delivery. The inventors found that a novel nanosystem allows improving platinum-based drug in vivo performance, kinetics and efficacy. In particular, the present invention re¬ lates to nanoparticles useful as drug delivery system, said nanoparticles being formed from at least: (a) platinum-based drug, (b) poly-L-arginine, and (c) hyaluronic acid. Particularly, the inventors tested these nanoparticles in terms of entrapment efficiency and also carried out in vitro experiments in 2D cell culture (viability studies o B6KPC3, A549 and HT-29 cells) and 3D cell model (spheroids made of HTC-1 16) and in vivo experiments (by injecting intravenously to mice said nanoparticles or comparative oxaliplatin solution) to prove their efficiency.
Type de document :
Brevet
Liste complète des métadonnées

https://hal.univ-angers.fr/hal-03142927
Contributeur : Laurent Lemaire <>
Soumis le : mardi 16 février 2021 - 13:55:28
Dernière modification le : mercredi 17 février 2021 - 03:27:19

Identifiants

  • HAL Id : hal-03142927, version 1

Citation

Giovanna Lollo, Jean-Pierre Benoit, Marie Brachet-Botineau. Drug delivery system for platinum-based drugs. France, Patent n° : WO 2020/053445 A1. 2020. ⟨hal-03142927⟩

Partager

Métriques

Consultations de la notice

51